<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Nov. 8, 2018 (HealthDay News) — For patients with stable coronary artery disease (CAD), very low levels of resting high-sensitivity cardiac troponin I (hs-cTnI) can rule out inducible myocardial ischemia, according to a study published online Nov. 6 in the Annals of Internal Medicine<\/i>.<\/p>\n
Muhammad Hammadah, M.D., from the Emory University School of Medicine in Atlanta, and colleagues conducted an observational study to examine whether low levels of hs-cTnI can identify those without inducible myocardial ischemia among individuals with stable CAD. A total of 589 patients were included in the derivation group and 118 were included in the validation cohort.<\/p>\n
The researchers found that in the derivation cohort, 10 of 101 patients with an hs-cTnI level less than 2.5 pg\/mL had inducible myocardial ischemia and three of 101 had inducible ischemia involving at least 10 percent of the myocardium. Four of 32 patients in the validation cohort with an hs-cTnI level less than 2.5 pg\/mL had inducible ischemia and two had ischemia of 10 percent or greater. No adverse events occurred in patients with an hs-cTnI level less than 2.5 pg\/mL after a median follow-up of three years in the derivation cohort, but 7 percent of those with an hs-cTnI level \u22652.5 pg\/mL had cardiovascular death or incident myocardial infarction.<\/p>\n
“A low plasma level of hs-cTnI identifies patients with CAD who have a very low risk for myocardial ischemia during stress testing and a low medium-term risk for adverse cardiovascular events,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n